Business Context and Reporting Period
This Form 8-K Current Report was filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on March 12, 2020. The registrant is a Delaware corporation with principal executive offices in Alameda, California. The filing addresses a corporate governance event rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 5.02 regarding the departure of a director and does not contain financial statements or operational metrics.
Material Changes
The material change reported is the resignation of John Mauldin from the AgeX Board of Directors, effective March 12, 2020. Mr. Mauldin stated his resignation was necessary to maintain his independence as a director of the company's subsidiary, Reverse Bioengineering, Inc. ("Reverse Bio"), and to focus his efforts on building Reverse Bio to pursue AgeX's ITR technology.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer regarding forward-looking statements, noting that actual results may differ materially from anticipated results due to various risk factors detailed in the company's periodic SEC reports. No specific financial guidance or outlook was provided in this document.
Investor Verification Checklist
- Verify the current composition of the AgeX Board of Directors following Mr. Mauldin's departure.
- Review the relationship and operational status between AgeX Therapeutics and its subsidiary, Reverse Bioengineering, Inc.
- Check subsequent filings for any impact on the company's strategic direction regarding ITR technology.